Monte Rosa Surges 20% Premarket on MRT-8102 Cardiovascular Data Review
GLUE has more than doubled off its 52-week low of $7.09.
Summary
Monte Rosa announced positive results for MRT-8102 in the GFORCE-1 Phase 1 study showing normalization of key pathogenic drivers of ASCVD in subjects with elevated CVD risk. MRT-8102 reduced median Lp(a) by 24%, calprotectin by 56%, S100A12 by 46%, SAA by 51%, IL-6 by 54%, hsCRP by 85%, and fibrinogen by 28%; no SAEs, TEAEs 33% vs 30% placebo. Phase 2 trials GFORCE-2, GEMINI-1, and GALAXY-1 planned. The company announced a conference call Thursday at 8 a.m. ET to review clinical results from an early-stage study of MRT-8102, a molecular glue degrader for elevated cardiovascular risk. The stock jumped 20% premarket to $14.32, signaling strong investor anticipation for the data. This follows the company's Q2 update showing $626M cash runway into 2029 and the recent Novartis milestone for MRT-6160. The data readout could materially de-risk the pipeline and validate the molecular glue platform. Watch the call for efficacy and safety details.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — MRT-8102 reduced median Lp(a) by 24%, calprotectin by 56%, S100A12 by 46%, SAA by 51%, IL-6 by 54%, hsCRP by 85%, and fibrinogen by 28%; no SAEs, TEAEs 33% vs 30% placebo. Phase 2 trials GFORCE-2, GEMINI-1, and GALAXY-1 planned.
At the time of this announcement, GLUE was trading at $14.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $7.09 to $25.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.